May 27, 2016 Francis S. Collins, M.D., Ph.D. Director National Institutes of Health Building 1 Room 26 Bethesda, MD 20814 Dear Dr. Collins: Per statutory requirement, enclosed you will find the 2015 FNIH Annual Report to NIH. The report is comprised of the following: • Brief FNIH overview • 2015 Allocation of NIH’s Statutory Contribution to the FNIH • 2015 Operating Revenues and Expenses • 2015 Program Revenues and Expenses • FNIH Board of Directors • 2015 NIH Proposal Review Committee Submissions to FNIH • FNIH Project Summaries through December 31, 2015 • 2015 Financial Statements and Independent Auditor Letter • 2015 FNIH Summary Annual Report You will find the first eight items together in the spiral bound booklet. The 2015 FNIH Summary Annual Report is a separate document included in the package. Please do not hesitate to contact me if you have any questions. Sincerely yours, Maria C. Freire, Ph.D. President and Executive Director cc: Steven M. Paul, M.D., Chairman 2015 Annual Report to the National Institutes of Health May 27, 2016 Table of Contents Tab One ………………………………………………….….….….….….………….Brief FNIH Overview Tab Two……………………………………..2015 Allocation of NIH’s Statutory Contribution to the FNIH Tab Three…..………………….……………………………………2015 Operating Revenues and Expenses Tab Four……………….……….………………………………....….2015 Program Revenues and Expenses Tab Five…..……………….………………………………………………………FNIH Board of Directors Tab Six……………………………………….2015 NIH Proposal Review Committee Submissions to FNIH Tab Seven…..………………...………………………FNIH Project Summaries through December 31, 2015 Tab Eight…………….……………....….2015 Financial Statements and Report of the Independent Auditors Enclosure…..…………………………………………………..………2015 FNIH Summary Annual Report The Foundation for the National Institutes of Health organizes productive research collaborations, incubates new research models and channels resources for maximum impact in order to support the mission of the National Institutes of Health, the largest biomedical research agency in the world, as it works to turn discovery into health. From 1996-2015, the Foundation raised almost $850 million, consistently generating over $80 per $1 of NIH support, therefore dramatically leveraging NIH’s yearly contribution. Rated by Charity Navigator as an organization that exceeds industry standards for effective management and efficient use of resources, the FNIH has partnered with the NIH to pioneer novel, mission-critical public- private partnerships that promote human health. Notably, 2015 marked ten years since the Edmond J. Safra Family Lodge opened its doors to the families of patients receiving care at the NIH Clinical Center. With a founding gift from Ms. Lily Safra and extensive support from private sector benefactors, the Lodge has provided a home away from home for those family members who are often the most important caregivers to patients experiencing serious illness. Whether it is raising funds for novel clinical trial models such as LUNG-MAP or responding to the NIH Office of the Director to design the Accelerating Medicines Partnership (AMP), the FNIH provides a place where private industry, academia, and government can come together to address critical health challenges. In this and other ways, the FNIH is a critical effector, implementer, steward and partner to the NIH. 2015 Allocation of NIH’s Statutory Contribution to the FNIH * Table 1 Activity Cost 1) Lease 12,000 sp. Feet of Office Space at FASEB$ 271,926 2) Unrecovered Program Salary & Benefits$ 294,824 3) Partial Operating Costs$ 65,966 4) Three key positions as outlined in $ 367,284 Memorandum dated October 15, 2014 Total$ 1,000,000 * 2015 Expenses Allocable to the NIH Appropriation$ 4,526,543 2015 Operating Revenues and Expenses Table 2 Program Administrative Fees 2015 Financial Support for Operating Activities Program Administrative Fees 3,188,303 64% NIH Appropriation NIH Appropriation 1,000,000 20% Other Income 371,650 7% Unrestricted Gifts 243,921 5% Other Income In‐Kind Contributions 336,239 7% Investment Income (124,170) ‐2% Unrestricted Gifts Total Revenue 4,901,442 In‐Kind Contributions 2015 Operating Expenses S&B (not recovered as direct S&B (not recovered as direct costs) 3,617,933 75% costs) Rent (not recovered as direct cost) 271,926 5% Other Overhead Costs 972,923 20% Rent (not recovered as direct Total Overhead Costs 4,832,734 cost) Current Appropriation as % of Total Overhead Costs 21% Other Overhead Costs 2015 Program Revenues and Expenses Table 3 Research Partnerships 2015 Financial Support for Programs Research Partnerships 30,604,224 96% Training Training 701,732 2% Events and Awards 660,288 2% Safra Family Lodge 39,738 0% Events and Awards Total Program Revenue 32,005,982 Safra Family Lodge 2015 Program Expenditures Research Partnerships Research Partnerships 54,949,820 96% Training 1,257,703 2% Training Events and Awards 603,293 1% Safra Family Lodge 277,018 0% Events and Awards Total Program Expenditures 57,087,834 Safra Family Lodge Board of Directors as of December 31, 2015 Charles A. Sanders, M.D. (Chairman) Retired Chairman and Chief Executive Officer, Glaxo Inc. Maria C. Freire, Ph.D. President and Executive Director, Foundation for the National Institutes of Health The Honorable John Edward Porter (Vice Chairman for Policy) Hogan Lovells US, LLP Solomon H. Snyder, M.D. (Vice Chairman for Science) Distinguished Service Professor of Neuroscience, Pharmacology & Psychiatry Solomon H. Snyder Department of Neuroscience at Johns Hopkins University Steven C. Mayer (Treasurer) Former Chief Executive Officer, CoGenesys, Inc. Mrs. William McCormick Blair, Jr. (Secretary) Director Emeritus, Albert & Mary Lasker Foundation Kathy Bloomgarden, Ph.D. Chief Executive Officer, Ruder Finn Inc. Mrs. William (Buffy) N. Cafritz Honorary Trustee, The John F. Kennedy Center for the Performing Arts James H. Donovan Managing Director, Goldman Sachs & Company; Adjunct Professor, University of Virginia; Trustee, Dana-Farber Cancer Institute Joseph M. Feczko, M.D. Retired Senior Vice President and Chief Medical Officer, Pfizer Inc Paul L. Herrling, Ph.D. Chairman, Novartis Institute for Tropical Disease Judy Lansing Kovler, Ph.D. Director, Kovler Foundation and Vice Chair of Sasha Bruce, Inc. Ronald L. Krall, M.D. Former Senior Vice-President and Chief Medical Officer, GlaxoSmithKline Freda C. Lewis-Hall, M.D., FAPA Chief Medical Officer, Senior Vice President, Pfizer Inc 1 Edison T. Liu, M.D., Ph.D. President & CEO, The Jackson Laboratory Ann Lurie President, Lurie Holdings; President and Treasurer, Ann and Robert H. Lurie Foundation Joel S. Marcus Chairman, Chief Executive Officer and Founder, Alexandria Real Estate Equities, Inc. and Alexandria Venture Investments Paul M. Montrone, Ph.D. Chairman, Perspecta Trust Martin J. Murphy Jr., Ph.D. DMedSc, FASCO Founding Chairman and Chief Executive Officer, AlphaMed Consulting, Inc. Steven M. Paul, M.D. President and Chief Executive Officer, Voyager Therapeutics, Inc. and Venture Partner at Third Rock Ventures Jillian Sackler, D.B.E. President and Chief Executive Officer, Dame Jillian & Dr. Arthur M. Sackler Foundation for the Arts, Sciences & Humanities Lily Safra Chairwoman, Edmond J. Safra Philanthropic Foundation Ellen V. Sigal, Ph.D. Chairperson, Friends of Cancer Research Nina K. Solarz Former Executive Director of Peace Links and the Fund for Peace Russell W. Steenberg Global Head, BlackRock Private Equity Partners Samuel O. Thier, M.D. Professor of Medicine and Health Care Policy, Emeritus, Harvard Medical School; Massachusetts General Hospital Anne Wojcicki Chief Executive Officer and Co-founder, 23andMe EX OFFICIO NON-VOTING DIRECTORS Stephen Ostroff, M.D. Acting Commissioner, Food and Drug Administration Francis S. Collins, M.D., Ph.D. Director, National Institutes of Health 2 DIRECTORS EMERITUS Paul Berg, Ph.D. Cahill Professor in Biochemistry (Emeritus), Stanford University School of Medicine Sherry Lansing Founder and Chief Executive Officer, The Sherry Lansing Foundation HONORARY DIRECTORS Luther W. Brady, M.D. Affiliate Faculty Member in the Department of Radiation Oncology at Drexel University; Former Chair of the Department of Radiation Oncology, MCP Hahnemann University Patrick C. Walsh, M.D. University Distinguished Service Professor, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions 3 2015 NIH Proposal Review Committee Submissions to FNIH 2015 NIH Proposal Review Committee Submissions UNDER CONSIDERATION Date FNIH R&D Pipeline Name of Project IC Project Description Update rec'd RFC Area NIH Archives Online: NLM 10/29/2015 The project involves digitizing completely, preserving N/A During its due diligence phase, the FNIH staff contacted 10 foundations, corporations, Legacies of Scientific for future generations, and making publicly available and individual philanthropists to gauge interest. Many of the most likely donors were Achievement via the NLM’s existing Digital Collections repository unwilling to provide definitive input absent a formal funding proposal. The FNIH the top-50 patron-requested manuscript collections submitted a $250,000 application to the Council on Library Information Resources held by the NLM’s History of Medicine Division. (CLIR), which will likely serve as a bellwether as to whether substantial funding is possible. A decision is expected by July 2016, after which the PPP Committee will determine how to proceed with the program. ACTIVE PROJECTS Date FNIH R&D Pipeline Name of Project IC Project Description Update rec'd RFC Area Research